Business Context and Reporting Period
This Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. on May 24, 2023. The report addresses a temporary delisting notice from Nasdaq and provides a corporate update regarding the filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2023.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Form 10-Q and the attached press release (Exhibit 99.1), which are not included in the provided text.
Material Changes and Events
- Nasdaq Delisting Notice: On May 24, 2023, the Company received notice from Nasdaq that it fell out of compliance with listing rules due to the failure to file its Form 10-Q for the quarter ended March 31, 2023, within the allowed five-day extension.
- Cause of Delay: The delay in filing was attributed to accounting complexities related to a convertible note held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B.
- Resolution: The Company filed the Form 10-Q on May 25, 2023, thereby regaining compliance with Nasdaq Listing Rules.
Guidance, Outlook, and Risks
The filing references a press release issued on May 26, 2023, containing a corporate update, but the text of that release is not provided. Consequently, no specific guidance, outlook, or management commentary is available in this document. The primary risk identified was the temporary loss of Nasdaq listing compliance due to accounting complexities.
Investor Verification Checklist
- Verify the specific financial results and cash position in the Form 10-Q filed on May 25, 2023.
- Review the details of the convertible note held by Alto Opportunity Master Fund to understand the accounting complexities cited.
- Confirm the current listing status on Nasdaq following the May 25, 2023 filing.
- Examine the attached press release (Exhibit 99.1) for any updated operational milestones or strategic shifts.